The European Brain Council (EBC) is pleased to launch the Rethinking Myasthenia Gravis (MG) Policy Brief, a key outcome of the two-year Rethinking Myasthenia Gravis project.
Launched during EBC’s Rare Disease Day event “Towards a Rare Brain Disease Ecosystem” in 2025, the project brings together researchers, clinicians, patient representatives, policymakers, and European Reference Networks to develop evidence-based recommendations aimed at improving the lives of people living with MG across Europe.
The Policy Brief builds on the Rethinking Myasthenia Gravis Advocacy Paper, released in February 2026, which highlighted the need for faster diagnosis, stronger multidisciplinary care, equitable access to innovative therapies, and greater integration of digital tools and patient-experienced data in MG care.
Despite significant advances in diagnostics and treatment, people living with MG continue to face diagnostic delays, fragmented care pathways, unequal access to specialist expertise and therapies, and insufficient recognition of the disease’s wider impact on mental health, cognition, and quality of life.
About Myasthenia Gravis
Myasthenia Gravis (MG) is a rare autoimmune disorder of the neuromuscular junction characterised by fluctuating muscle weakness and fatigue. Despite affecting more than 700,000 people worldwide and approximately 1 in 5,000 people in Europe, MG remains under-recognised and often misunderstood. Beyond its physical symptoms, the condition can have a significant impact on daily functioning, mental wellbeing, social participation, and quality of life for people living with the disease and their caregivers.
Key priorities of the Rethinking MG Policy Brief
- Embedding multidisciplinary care pathways
- Ensuring equitable access to innovative therapies
- Addressing the socioeconomic and psychological burden on patients and caregivers
- Reducing diagnostic delay and misdiagnosis
- Harnessing digital tools and data to improve MG management
The Policy Brief also presents recommendations at European, national, and global levels to strengthen care pathways, improve access to diagnostics and treatments, support patients and caregivers, and advance coordinated action on rare neurological diseases.
By positioning MG as a practical example of how rare disease and brain health commitments can be translated into action, the Policy Brief aims to support more equitable, patient-centred care across Europe.